AbbVie (ABBV) vs. Eli Lilly (LLY)

Company Profile

AbbVie (ABBV) and Eli Lilly (LLY) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but ABBV is classified in Biotechnology while LLY is classified in Pharmaceuticals.

Historical Performance

Historical Performance at a Glance

Profitability

Both AbbVie (ABBV) at 95.59% and Eli Lilly (LLY) at 101.31% rank in the top quartile for Return on Equity (TTM) among industry peers, indicating strong returns on shareholders’ equity.

Eli Lilly (LLY) at 34.99% ranks in the top quartile for Net Profit Margin (TTM), ahead of AbbVie (ABBV) at 6.91%, which sits closer to the industry mid-range.

Both AbbVie (ABBV) at 24.65% and Eli Lilly (LLY) at 43.63% rank in the top quartile for Operating Profit Margin (TTM) among industry peers, indicating both companies convert revenue into operating income more strongly than typical competitors.

Profitability at a Glance

Financial Strength

Both AbbVie (ABBV) at 0.67 and Eli Lilly (LLY) at 1.50 run Current Ratio (MRQ) in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

Eli Lilly (LLY) at 1.39 sits in the higher-leverage quartile relative to peers, but AbbVie (ABBV) at 49.22 is higher still, above its industry benchmark range.

Eli Lilly (LLY) at 20.36 ranks in the top quartile for Interest Coverage Ratio (TTM), ahead of AbbVie (ABBV) at 3.46, which sits around the industry mid-range.

Financial Strength at a Glance

Growth

Revenue Growth

Revenue Growth at a Glance

EPS Growth

EPS Growth at a Glance

Dividend

Both AbbVie (ABBV) at 3.11% and Eli Lilly (LLY) at 0.57% report Dividend Yield (TTM) near their industry mid-ranges, so neither company stands out strongly from peers on cash yield relative to share price.

AbbVie (ABBV) reports an unusual Dividend Payout Ratio (TTM) of 275.84% — outside the typical 0–100% range, indicating either negative earnings (negative ratio) or dividends above current-period earnings (above 100%), both signaling sustainability concerns. Meanwhile Eli Lilly (LLY) reports 22.10%, ranking against industry peers normally.

Dividend at a Glance

Valuation

Eli Lilly (LLY) at 38.63 hovers around the typical industry Price-to-Earnings Ratio (TTM), while AbbVie (ABBV) at 88.76 sits above its industry benchmark range — an elevated trailing earnings multiple for ABBV relative to peers.

Both AbbVie (ABBV) at 6.13 and Eli Lilly (LLY) at 13.51 post Price-to-Sales Ratio (TTM) near the typical industry midpoint — neither company stands out strongly from peers on trailing revenue multiple.

Both AbbVie (ABBV) at 261.01 and Eli Lilly (LLY) at 27.85 sit above their industries’ benchmark ranges for Price-to-Book Ratio (MRQ), pointing to unusually high book-value multiples relative to peers.

Valuation at a Glance